Difference between revisions of "Clear cell renal cell carcinoma"
Jump to navigation
Jump to search
(Created page with "{{#lst:Section editor transclusions|gu}} ''Are you looking for a regimen but can't find it here? It is possible that we've moved it to the Renal_cell_carcinoma_-_historical|...") |
Warner-admin (talk | contribs) |
||
| Line 21: | Line 21: | ||
==[http://www.esmo.org/ ESMO]== | ==[http://www.esmo.org/ ESMO]== | ||
*'''2021:''' Powles [https://doi.org/10.1016/j.annonc.2020.11.016 Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] | *'''2021:''' Powles [https://doi.org/10.1016/j.annonc.2020.11.016 Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] | ||
| + | |||
| + | =Metastatic disease, first-line= | ||
| + | ==Pembrolizumab monotherapy {{#subobject:18jguz|Regimen=1}}== | ||
| + | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
| + | |- | ||
| + | |[[#top|back to top]] | ||
| + | |} | ||
| + | ===Regimen {{#subobject:ahgz17|Variant=1}}=== | ||
| + | {| class="wikitable sortable" style="width: 80%; text-align:center;" | ||
| + | !style="width: 25%"|Study | ||
| + | !style="width: 25%"|Years of enrollment | ||
| + | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
| + | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
| + | |- | ||
| + | |[https://doi.org/10.1200/jco.20.02363 McDermott et al. 2021 (KEYNOTE-427)] | ||
| + | |2016-NR | ||
| + | | style="background-color:#91cf61" |Phase 2 | ||
| + | |ORR: 36% | ||
| + | |- | ||
| + | |} | ||
| + | ''Note: this reference describes the clear cell cohort of KEYNOTE-427.'' | ||
| + | ====Immunotherapy==== | ||
| + | *[[Pembrolizumab (Keytruda)]] 200 mg IV once on day 1 | ||
| + | '''21-day cycle for up to 36 cycles (2 years)''' | ||
| + | ===References=== | ||
| + | #'''KEYNOTE-427:''' McDermott DF, Lee JL, Bjarnason GA, Larkin JMG, Gafanov RA, Kochenderfer MD, Jensen NV, Donskov F, Malik J, Poprach A, Tykodi SS, Alonso-Gordoa T, Cho DC, Geertsen PF, Climent Duran MA, DiSimone C, Silverman RK, Perini RF, Schloss C, Atkins MB. Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. J Clin Oncol. 2021 Mar 20;39(9):1020-1028. Epub 2021 Feb 2. [https://doi.org/10.1200/jco.20.02363 link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/33529051/ PubMed] NCT02853344 | ||
=Metastatic disease, second-line= | =Metastatic disease, second-line= | ||
Revision as of 13:11, 7 July 2022
Section editor transclusions
Are you looking for a regimen but can't find it here? It is possible that we've moved it to the historical regimens page. For placebo or observational studies in this condition, please visit this page. If you still can't find it, please let us know so we can add it!
There are several related dedicated pages:
- General RCC page: Renal cell carcinoma
- Histology-specific:
- Biomarker-specific:
34 regimens on this page
48 variants on this page
|
Guidelines
EAU
- 2016: Powles et al. Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy PubMed
ESMO
Metastatic disease, first-line
Pembrolizumab monotherapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Efficacy |
|---|---|---|---|
| McDermott et al. 2021 (KEYNOTE-427) | 2016-NR | Phase 2 | ORR: 36% |
Note: this reference describes the clear cell cohort of KEYNOTE-427.
Immunotherapy
- Pembrolizumab (Keytruda) 200 mg IV once on day 1
21-day cycle for up to 36 cycles (2 years)
References
- KEYNOTE-427: McDermott DF, Lee JL, Bjarnason GA, Larkin JMG, Gafanov RA, Kochenderfer MD, Jensen NV, Donskov F, Malik J, Poprach A, Tykodi SS, Alonso-Gordoa T, Cho DC, Geertsen PF, Climent Duran MA, DiSimone C, Silverman RK, Perini RF, Schloss C, Atkins MB. Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. J Clin Oncol. 2021 Mar 20;39(9):1020-1028. Epub 2021 Feb 2. link to original article contains protocol PubMed NCT02853344
Metastatic disease, second-line
Nivolumab monotherapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| McFarlane et al. 2020 (CheckMate 374) | 2015-2016 | Phase 3b/4 |
Immunotherapy
- Nivolumab (Opdivo) 240 mg IV once on day 1
14-day cycles
References
- CheckMate 374: McFarlane JJ, Kochenderfer MD, Olsen MR, Bauer TM, Molina A, Hauke RJ, Reeves JA, Babu S, Van Veldhuizen P, Somer B, Gunuganti V, Schnadig I, George S, Page RD, Arrowsmith E, Jain RK, Zhang J, McHenry MB, Johansen JL, Vogelzang NJ. Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. Clin Genitourin Cancer. 2020 Dec;18(6):469-476.e4. Epub 2020 Jun 14. link to original article contains protocol PubMed NCT02596035
Sorafenib monotherapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Escudier et al. 2007 (TARGETRCC) | 2003-2005 | Phase 3 (E-RT-esc) | Placebo | Did not meet primary endpoint of OS1 |
1Reported efficacy for TARGET is based on the 2009 update.
Note that TARGET should not be confused with the study by the same name in breast cancer.
Targeted therapy
- Sorafenib (Nexavar) 400 mg PO twice per day
- Can be decreased to 400 mg PO once per day or 400 mg PO every other day if needed due to toxicity
Continued indefinitely
References
- TARGET: Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):125-34. Erratum in: N Engl J Med. 2007 Jul 12;357(2):203. link to original article contains verified protocol PubMed NCT00073307
- Update: Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009 Jul 10;27(20):3312-8. Epub 2009 May 18. link to original article PubMed
- Subgroup analysis: Hutson TE, Bellmunt J, Porta C, Szczylik C, Staehler M, Nadel A, Anderson S, Bukowski R, Eisen T, Escudier B; Sorafenib TARGET Clinical Trial Group. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer. 2010 Sep;46(13):2432-40. Epub 2010 Jul 23. link to original article contains verified protocol PubMed